Drugs / L-830982
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00129441 | Aug 2005 → Jan 2008 | schizophrenia | University of Pittsburgh | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-830982 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00129441 ↗ |
| Known as | Merck L-830982 | “The goal of this study is to determine whether the short-term (4 week), double-blind administration of Merck L-830982 provides evidence of improvement in cognitive functioning...” NCT00129441 ↗ |
| Action | Activate | “selective agonist activity at GABA(A) receptors containing alpha(2) subunits” PMID 18923067 ↗ Oct 2008 |
| Modality | Small molecule | “a benzodiazepine-like agent with selective activity at GABA(A) receptors containing alpha(2) or alpha(3) subunits” PMID 18923067 ↗ Oct 2008 |